Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.44 |
| ▸ | PHGDH | O43175 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27311808 | 0.92 | MEN1 (0.53) | MEN1KMT2ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL13841232 | 0.87 | MEN1 (0.47) | MEN1KMT2ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL10276562 | 0.87 | MEN1 (0.47) | MEN1KMT2ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL616596 | 0.84 | KMT2A (0.56) | MEN1KMT2ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL377675 | 0.82 | KMT2A (0.55) | MEN1KMT2ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL18697080 | 0.80 | KMT2A (0.53) | MEN1KMT2ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL880655 | 0.80 | KMT2A (0.53) | MEN1KMT2ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL27478098 | 0.80 | KMT2A (0.53) | MEN1KMT2ASMN1; SMN2ALDH1A1MAPT | |
| SCHEMBL282864 | 0.80 | — | — | |
| SCHEMBL12832981 | 0.79 | ALDH1A1 (0.48) | MEN1KMT2ASMN1; SMN2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3628045-B1 | COMPOUNDS | UNIV SHEFFIELD (GB) | 2024-07-03 | — | — | EP | disclosed |
| WO-2024081363-A1 | COMPOSITION COMPRISING A FIRST RAS INHIBITOR, SECOND RAS INHIBITOR AND A SHP2 INHIBITOR FOR USE IN THE TREATMENT OF CANCER | Revolution Medicines, Inc. (US) | 2024-04-18 | — | — | WO | disclosed |
| US-10954229-B2 | GPR119 agonist compounds | MANKIND PHARMA LTD. (IN) | 2021-03-23 | — | — | US | disclosed |
| US-20200317661-A1 | NOVEL GPR119 AGONIST COMPOUNDS | MANKIND PHARMA LTD. (IN) | 2020-10-08 | — | — | US | disclosed |
| US-10752622-B2 | GPR119 agonist compounds | MANKIND PHARMA LTD. (IN) | 2020-08-25 | — | — | US | disclosed |
| US-20190127363-A1 | NOVEL GPR119 AGONIST COMPOUNDS | MANKIND PHARMA LTD. (IN) | 2019-05-02 | — | — | US | disclosed |
| US-10208030-B2 | GPR119 agonist compounds | MANKIND PHARMA LTD. (IN) | 2019-02-19 | — | — | US | disclosed |
| EP-2969000-B1 | NEW COMPOUNDS | PROXIMAGEN LTD (GB) | 2018-02-21 | — | — | EP | disclosed |
| WO-2017175068-A1 | THIAZOLOPYRIDINE DERIVATIVES AS GPR119 AGONISTS | MANKIND PHARMA LTD. (IN) | 2017-10-12 | — | — | WO | disclosed |
| WO-2017175066-A1 | HETEROCYCLIC GPR119 AGONIST COMPOUNDS | MANKIND PHARMA LTD. (IN) | 2017-10-12 | — | — | WO | disclosed |
| WO-2008104597-A2 | SULFONYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-09-04 | — | — | WO | disclosed |
| US-20080207728-A1 | BICYCLIC ACYLTRYPTOPHANOLS | BAYER SCHERING PHARMA AG (DE) | 2008-08-28 | — | — | US | disclosed |
| US-20070244104-A1 | THIAZOLYL-DIHYDRO-QUINAZOLINE | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-18 | — | — | US | disclosed |
| US-7268150-B2 | 2-cyano-4-fluoropyrrolidine derivative or its salt | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2007-09-11 | — | — | US | disclosed |
| US-7268150-B2 | 2-cyano-4-fluoropyrrolidine derivative or its salt | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2007-09-11 | — | — | US | disclosed |
| US-7262206-B2 | Cycloalkyl—containing 5-acylindolinones, the preparation thereof and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-28 | — | — | US | disclosed |
| US-7262206-B2 | Cycloalkyl—containing 5-acylindolinones, the preparation thereof and their use as medicaments | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-28 | — | — | US | disclosed |
| WO-2007081897-A2 | FUSED TRIAZOLE TACHYKININ RECEPTOR ANTAGONISTS | MERCK & CO., INC. (US) | 2007-07-19 | — | — | WO | disclosed |
| US-7157580-B2 | Aminopyrimidine and aminopyridine anti-inflammation agents | ROCHE PALO ALTO LLC (US) | 2007-01-02 | — | — | US | disclosed |
| US-7157580-B2 | Aminopyrimidine and aminopyridine anti-inflammation agents | ROCHE PALO ALTO LLC (US) | 2007-01-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317661-A1 | NOVEL GPR119 AGONIST COMPOUNDS | GPR119, GPR84, GPR88 | MEN1 3239/4885KMT2A 2754/4885SMN1; SMN2 2548/4885 |
| US-20080207728-A1 | BICYCLIC ACYLTRYPTOPHANOLS | FSHR, GNRHR, TPH1 | MEN1 420/4885KMT2A 1405/4885SMN1; SMN2 4132/4885 |
| US-10752622-B2 | GPR119 agonist compounds | GPR119, GPR84, GPR65 | MEN1 3197/4885KMT2A 3467/4885SMN1; SMN2 2380/4885 |
| US-20070244104-A1 | THIAZOLYL-DIHYDRO-QUINAZOLINE | QDPR, NQO2, CYP3A4 | MEN1 729/4885KMT2A 3930/4885SMN1; SMN2 3095/4885 |
| US-10954229-B2 | GPR119 agonist compounds | GPR119, GPR84, GPR65 | MEN1 3197/4885KMT2A 3467/4885SMN1; SMN2 2380/4885 |
| US-10208030-B2 | GPR119 agonist compounds | GPR119, GPR84, GPR65 | MEN1 3197/4885KMT2A 3467/4885SMN1; SMN2 2380/4885 |
| US-20190127363-A1 | NOVEL GPR119 AGONIST COMPOUNDS | GPR119, GPR84, GPR88 | MEN1 3239/4885KMT2A 2754/4885SMN1; SMN2 2548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.